Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells

Biochemical Pharmacology

Volumn 80, Issue 11, 2010, Pages 1700-1707

  Mencarelli, Andrea ^a   Migliorati, Marco ^a   Barbanti, Miriam ^c   Cipriani, Sabrina ^a   Palladino, Giuseppe ^a   Distrutti, Eleonora ^b   Renga, Barbara ^a   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c Alfa Wassermann SpA   (Italy)

Author keywords

Colon epithelial cells; Detoxification system; Inflammatory bowel diseases (IBD); Pregnane X receptor (PXR); Rifaximin

Indexed keywords

PREGNANE X RECEPTOR; RIFAXIMIN; SMALL INTERFERING RNA; TUMOR NECROSIS FACTOR ALPHA; NONSTEROID ANTIINFLAMMATORY AGENT; RIFAMYCIN; STEROID RECEPTOR;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; COLON BIOPSY; DETOXIFICATION; DOWN REGULATION; DRUG METABOLISM; ENTERITIS; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; INTESTINE EPITHELIUM CELL; PRIORITY JOURNAL; ULCERATIVE COLITIS; ADULT; CELL LINE; COLON; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; DRUG INACTIVATION; FEMALE; HEPG2 CELL LINE; INTESTINE MUCOSA; MALE; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL LINE; COLON; FEMALE; HEP G2 CELLS; HUMANS; INTESTINAL MUCOSA; MALE; METABOLIC DETOXICATION, DRUG; RECEPTORS, STEROID; RIFAMYCINS; SIGNAL TRANSDUCTION; INACTIVATION, METABOLIC;

EID: 77957902464     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.08.022     Document Type: Article

References (38)

1. Scholmerich J. New developments in aetiological mechanisms of inflammatory bowel disease. Eur J Gastroenterol Hepatol 2003, 15:585-586.
2. Rogler G. Update in inflammatory bowel disease pathogenesis. Curr Opin Gastroenterol 2004, 20:311-317.
3. Schmidt C., Stallmach A. Etiology and pathogenesis of inflammatory bowel disease. Minerva Gastroenterol Dietol 2005, 51:127-145.
4. Bamias G., Nyce M.R., De La Rue S.A., Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 2005, 143:895-904.
5. Ahmed F.E. Role of genes, the environment and their interactions in the etiology of inflammatory bowel diseases. Expert Rev Mol Diagn 2006, 6:345-363.
6. Langmann T., Schmitz G. Loss of detoxification in inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol 2006, 3:358-359.
7. Wolf C.R., Seilman S., Oesch F., Mayer R.T., Burke M.D. Multiple forms of cytochrome P-450 related to forms induced marginally by phenobarbital. Differences in structure and in the metabolism of alkoxyresorufins. Biochem J 1986, 240:27-33.
8. Gonzalez F.J., Gelboin H.V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev 1994, 26:165-183.
9. Bergheim I., Bode C., Parlesak A. Distribution of cytochrome P450 2C, 2E1, 3A4, and 3A5 in human colon mucosa. BMC Clin Pharmacol 2005, 5:4.
10. Sarikaya D., Bilgen C., Kamataki T., Topcu Z. Comparative cytochrome P450-1A1, -2A6, -2B6, -2C, -2D6, -2E1, -3A5 and -4B1 expressions in human larynx tissue analysed at mRNA level. Biopharm Drug Dispos 2006, 27:353-359.
11. Xie W., Uppal H., Saini S.P., Mu Y., Little J.M., Radominska-Pandya A., et al. Orphan nuclear receptor-mediated xenobiotic regulation in drug metabolism. Drug Discov Today 2004, 9:442-449.
12. Roediger W.E., Babidge W. Human colonocyte detoxification. Gut 1997, 41:731-734.
13. Kliewer S.A., Goodwin B., Willson T.M. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 2002, 23:687-702.
14. Rosenfeld J.M., Vargas R., Xie W., Evans R.M. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol Endocrinol 2003, 17:1268-1282.
15. Sonoda J., Chong L.W., Downes M., Barish G.D., Coulter S., Liddle C., et al. Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proc Natl Acad Sci U S A 2005, 102:2198-2203.
16. Langmann T., Moehle C., Mauerer R., Scharl M., Liebisch G., Zahn A., et al. Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes. Gastroenterology 2004, 127:26-40.
17. Shah Y.M., Ma X., Morimura K., Kim I., Gonzalez F.J. Pregnane X receptor activation ameliorates DSS-induced inflammatory bowel disease via inhibition of NF-κB target gene expression. Am J Physiol 2007, 292:G1114-G1122.
18. Ghosh S., Karin M. Missing pieces in the NF-κB puzzle. Cell 2002, 109:S81-S96.
19. Gu X., Ke S., Liu D., Sheng T., Thomas P.E., Rabson A.B., et al. Role of NF-κB in regulation of PXR-mediated gene expression, a mechanism for the suppression of cytochrome P-4503A4 by pro-inflammatory agents. J Biol Chem 2006, 281:17882-17889.
20. Morgan E.T. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 1997, 29:1129-1188.
21. Klaassen C.D., Aleksunes L.M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol Rev 2010, 62:1-96.
22. Panwala C.M., Jones J.C., Viney J.L. A novel model of inflammatory bowel disease: mice deficient for the multiple drug resistance gene, mdr1a, spontaneously develop colitis. J Immunol 1998, 161:5733-5744.
23. Schwab M., Schaeffeler E., Marx C., Fromm M.F., Kaskas B., Metzler J., et al. Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology 2003, 124:26-33.
24. Brant S.R., Panhuysen C.I., Nicolae D., Reddy D.M., Bonen D.K., Karaliukas R., et al. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am J Hum Genet 2003, 73:1282-1292.
25. Ma X., Shah Y.M., Guo G.L., Wang T., Krausz K.W., Idle J.R., et al. Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 2007, 322:391-398.
26. Danielson P. The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans. Curr Drug Metab 2002, 3:561-597.
27. Bogaards J.J., van Ommen B., van Bladeren P.J. Purification and characterization of eight glutathione S-transferase isoenzymes of hamster. Comparison of subunit composition of enzymes from liver, kidney, testis, pancreas and trachea. Biochem J 1992, 286:383-388.
28. Lilla C., Risch A., Verla-Tebit E., Hoffmeister M., Brenner H., Chang-Claude J. SULT1A1 genotype and susceptibility to colorectal cancer. Int J Cancer 2007, 120:201-206.
29. Ho G.T., Moodie F.M., Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?. Gut 2003, 52:759-766.
30. Langmann T., Mauerer R., Zahn A., Moehle C., Probst M., Stremmel W., et al. Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem 2003, 49:230-238.
31. Gerard L., Garey K.W., DuPont H.L. Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections. Expert Rev Anti Infect Ther 2005, 3:201-211.
32. Jiang Z.D., DuPont H.L. Rifaximin: in vitro and in vivo antibacterial activity. Chemotherapy 2005, 51:67-72.
33. Debbia E.A., Maioli E., Roveta S., Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. J Chemother 2008, 20:186-194.
34. Fiorucci S., Distrutti E., Mencarelli A., Barbanti M., Palazzini E., Morelli A. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 2002, 66:246-256.
35. Bass N.M., Mullen K.D., Sanyal A., Poordad F., Neff G., Leevy C.B., et al. Rifaximin treatment in hepatic encephalopathy. N Engl J Med 2010, 362:1071-1081.
36. Scarpignato C., Pelosini I. Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential. Chemotherapy 2005, 51:36-66.
37. Arrese M., Karpen S.J. Nuclear receptors, inflammation, and liver disease: insights for cholestatic and fatty liver diseases. Clin Pharmacol Ther 2010, 87:473-478.
38. McKay L.I., Cidlowski J.A. Molecular control of immune/inflammatory responses: interactions between nuclear factor-κB and steroid receptor-signaling pathways. Endocr Rev 1999, 20:435-459.